Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Marciniec, Michał" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Intranasal insulin and cell-penetrating peptides in the treatment of Alzheimer’s disease
    Autorzy:
    Marciniec, Michał
    Kulczyński, Marcin
    Nowak, Andrzej
    Kwak, Wojciech
    Powiązania:
    https://bibliotekanauki.pl/articles/1178799.pdf
    Data publikacji:
    2017
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Alzheimer's disease
    GLP-1 agonists
    anti-diabetic drugs
    cell-penetrating peptides
    cognitive function
    dementia
    intranasal insulin
    Opis:
    Alzheimer’s disease (AD) is the most common cause of dementia and is responsible for up to 75% of the nearly 47 million dementia cases worldwide. AD is the clinical manifestation of toxic β-amyloid and neurofibrillary tangles accumulation caused by altered proteostasis. Due to not fully understood molecular mechanisms of AD only symptomatic treatment is available. Considering that cognitive decline is associated with insulin resistance, metabolic alterations may be the primary causes of the AD and insulin therapy is proposed as a novel approach in AD treatment. Intranasal administration of insulin appears to be a profitable solution for drug delivery to the brain due to blood-brain barrier bypassing, higher bioavailability and the lack of systemic side effects. When applying this method, insulin is sprayed into the nasal cavity, enters the mucosa and is transported along the axon bundles to the brain. Clinical trials of AD treatment with intranasal insulin revealed improvement in cognition, verbal memory and functional status. Notably, enhancement in memory and cognition were observed both in healthy adults and in AD patients and were ApoE ε4-related. The use of cell-penetrating peptides (CPPs) improve cellular uptake of insulin, enhance bioavailability and increase the direct insulin transport into the deeper regions of the brain such as the olfactory bulb and hippocampus. Animal studies revealed beneficial effects on AD symptoms of other molecules applied in connection with CPPs and most of them approve CPPs formulations for use in clinical trials. This review article summarize clinical trials results of intranasal insulin administration in AD treatment and propose the use of CPPs as an additive to conventional and experimental therapies for AD.
    Źródło:
    World Scientific News; 2017, 90; 138-149
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Current Highlights in the Use of Magnetic Resonance Spectroscopy in Multiple Sclerosis
    Autorzy:
    Kulczyński, Marcin
    Walicka, Alicja
    Marciniec, Michał
    Sapko, Klaudia
    Dyndor, Katarzyna
    Powiązania:
    https://bibliotekanauki.pl/articles/1058090.pdf
    Data publikacji:
    2019
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Multiple sclerosis
    N-acetylaspartate
    brain metabolites
    demyelination
    magnetic resonance imaging
    magnetic resonance spectroscopy
    Opis:
    Magnetic resonance spectroscopy is a non-invasive method used to measure concentrations of selected metabolites in brain such as: N-acetylaspartate, creatine, choline, glutamic acid, myo-inositol, lactic acid or γ-aminobutyric acid. The MRS allows the researcher to obtain information about biochemical composition in selected localizations of the examined CNS and is based on the interpretation of spectra of specific chemical compounds. The aim of this study is a literature review of papers from last 5 years involving the use of MRS in multiple sclerosis. Magnetic resonance spectroscopy is a modern, promising metabolomic imaging method enabling the assessment of brain metabolite concentrations and the dynamism of their changes in healthy people and patients suffering from multiple sclerosis at every stage of the disease. MRS is helpful not only in correlating changes in metabolite concentrations at various central nervous system locations with clinical manifestations, but is also an increasingly improving tool for predicting disease progression. Magnetic resonance spectroscopy may also be useful in more specific clinical situations such as differential diagnosis between multiple sclerosis and Devic’s syndrome or between tumefactive demyelinating lesions and gliomas. Especially in the latter case, the development of this technology may in the future result in the possibility of avoiding invasive biopsy in patients during the diagnosis of focal changes in the CNS. One should also not forget about the role that MRS may play in the future in monitoring the course of treatment with modern MS drugs, not only in everyday clinical practice but also at the stage of clinical trials. The development of fast MRS techniques, significantly shortening the acquisition time and 7 T magnetic resonance spectroscopy, precise and repeatable method of quantitative analysis of brain metabolites may be particularly helpful in achieving these goals.
    Źródło:
    World Scientific News; 2019, 134, 2; 187-197
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prevalence of respiratory tract infections and differences in antibiotic treatment in young adults in various countries – preliminary data from the multinational online survey
    Autorzy:
    Kulczyński, Marcin
    Chudzik, Robert
    Tomaszewski, Mateusz
    Marciniec, Michał
    Papuć, Ewa
    Powiązania:
    https://bibliotekanauki.pl/articles/1164544.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Respiratory tract infections
    antibiotic therapy
    communicable diseases
    Opis:
    Respiratory tract infections are the most common communicable diseases, which include pharyngitis, otitis media, rhinosinusitis, laryngitis, bronchitis and pneumonia. Although the majority of pathogenic agents responsible for these conditions are cosmopolitan, the differences in frequency and severity of these diseases associated with climate and living conditions may appear. The aim of the study is to assess if there are significant differences in frequency and severity of respiratory tract infections in different countries. A survey, consisting of 49 questions involving the frequency of respiratory tract infections, antibiotics’ usage and demographic data was delivered to the users of a social network used to finding penfriends from abroad. Collected data was statistically analyzed and compared with climate conditions and economic indices in different countries. 462 respondents, aged 12-79 (mean age 25,15 ± 9,43, median 23) from 119 countries submitted their answers. First raw, preliminary data describe a prevalence of different types of respiratory tract infections and commonness of antibiotic therapy. This initial report with preliminary results of the survey should be a first step towards determining the differences in frequency and severity of respiratory tract infections, as well as in antibiotic treatment. Data gained during the survey need further analysis.
    Źródło:
    World Scientific News; 2018, 107; 46-57
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The comparison of tenecteplase and alteplase in acute stroke treatment: meta-analysis of 5 randomized clinical trials
    Autorzy:
    Marciniec, Michał
    Szczepańska-Szerej, Anna
    Kulczyński, Marcin
    Popek-Marciniec, Sylwia
    Wyjadłowska, Karolina
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177755.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    alteplase
    cerebral infarction
    ischemic stroke
    rt-PA
    tenecteplase
    thrombolysis
    Opis:
    Thrombolysis with the use of intravenously administrated alteplase is the only approved thrombolytic treatment of acute ischemic stroke. Tenecteplase is a fibrinolytic protein bioengineered from human tissue plasminogen activator with higher fibrin specificity, enhanced affinity to fibrin-rich clots, faster clot lysis and prolonged plasma half-life. The aim of this study was to determine which thrombolytic therapy (tenecteplase versus alteplase) provides better efficacy and safety outcomes. Eligible studies for meta-analysis published from their inception to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Five studies comprising 1529 patients were included. Tenecteplase 0,25mg/kg administration resulted in significantly higher number of patients with excellent score (0-1) in modified Rankin Scale at 90 days compared to alteplase group (RR 1,30, p=0,0215, 95% CI 1,04–1,62). Additionally, more patients treated with tenecteplase 0,25 mg/kg tended to develop favorable score changes in NIHSS at 24 hours after stroke onset (>8 point improvement, scale quantifying stroke severity) compared to alteplase treatment (RR 1,60, p=0,0545, 95% CI 0,99–2,58). No above correlation were observed in higher dose of tenecteplase group (0,4 mg/kg). There were no significant differences in the frequency of symptomatic intracerebral hemorrhage (ICH) and the mortality rates within 90 days after stroke onset in comparison of tenecteplase and alteplase groups. Tenecteplase 0,25 mg/kg administration in acute ischemic stroke resulted in better functional outcome at 90 days after ischemic stroke onset and tended to restrict the severity of stroke at 24 hours in NIHSS compared to alteplase 0,9 mg/kg. The frequency of symptomatic ICH occurrence and mortality within 3 months between tenecteplase and alteplase were comparable.
    Źródło:
    World Scientific News; 2018, 100; 61-73
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prevention of seizures after ischemic stroke: association between statin use and the risk of seizures
    Autorzy:
    Marciniec, Michał
    Popek-Marciniec, Sylwia
    Kulczyński, Marcin
    Pasterczyk, Katarzyna
    Szczepańska-Szerej, Anna
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177817.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    HMG-CoA reductase inhibitor
    Post-stroke seizure
    epilepsy
    ischemic stroke
    rt-PA
    statin
    Opis:
    More than 50 million people worldwide suffer from epilepsy. In approximately 50% cases of newly diagnosed patients over 60 years of age seizures are related to stroke. Post-stroke lesions in brain tissue may result in 7 fold increase risk of seizures compared to the general population. The most significant risk factors for post-stroke seizures (PSS) and post-stroke epilepsy (PSE) include stroke severity, intracerebral or subarachnoid hemorrhage and cortical involvement. Increased incidence of PSS was also observed in younger patients especially with previous early PSS occurrence. Statins (HMG-CoA reductase inhibitors) are a class of lipid-lowering medications characterized by neuroprotective and antiepileptic effects. The main result of the performed studies was significantly reduced risk of developing PSS associated with a post-stroke, but not pre-stroke statin use. Moderate to high doses of statin and early administration in acute phase of stroke potentiated the beneficial effects of the treatment. The evidences for the association between PSS prevention and statin treatment become more significant, however the most recent AHA/ASA recommendations do not include any medications in the PSS prophylaxis. This article summarizes the current knowledge about the prediction and prevention of PSS and PSE.
    Źródło:
    World Scientific News; 2018, 99; 181-192
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The effectiveness of patent foramen ovale closure and antiplatelet or anticoagulant therapies for cryptogenic ischemic stroke
    Autorzy:
    Marciniec, Michał
    Szczepańska-Szerej, Anna
    Kulczyński, Marcin
    Popek-Marciniec, Sylwia
    Pasterczyk, Katarzyna
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177466.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Anticoagulation Agents
    Antiplatelet Agents
    Cerebral Infarction
    Cerebrovascular Stroke
    Patent Foramen Ovale
    Opis:
    Patent foramen ovale (PFO) occurs in approximately 50% cryptogenic strokes cases. One of the most clinically important consequences of PFO is paradoxical embolization of venous thrombus resulting in recurrent stroke. The aim of this meta-analysis is to compare the efficacy and safety of PFO closure and antiplatelet or anticoagulant therapy alone (medical therapy, MT) in the secondary stroke prevention. Eligible studies for meta-analysis published from May 2008 to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Three studies comprising 2’307 patients were included. The main outcomes were: recurrent stroke occurrence during follow-up period, the frequency of serious adverse events (SAE) and the mortality rate. Statistical significance was found in the assessment of recurrent stroke occurrence when the comparison referred to PFO closure and antiplatelet therapy (RR 0,30, p < 0,05, 95% CI 0,11 – 0,85). There were no significant differences between PFO closure and MT in the frequency of SAE occurrence (RR 1,03, p = 0,73) and mortality rates (RR 0,69, p = 0,39). Current clinical data indicate that PFO closure devices applied to the carefully selected group of young and middle-aged patients with cryptogenic ischemic stroke may be as or more effective than antiplatelet therapy.
    Źródło:
    World Scientific News; 2018, 102; 47-58
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Progressive forms of multiple sclerosis: disease-modifying therapy review
    Autorzy:
    Sapko, Klaudia
    Szczepańska-Szerej, Anna
    Jamroz-Wiśniewska, Anna
    Kulczyński, Marcin
    Marciniec, Michał
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1167060.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Disease-modifying drugs
    Multiple sclerosis
    New therapy
    Primary-progressive MS
    Secondary-progressive MS
    Opis:
    Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.
    Źródło:
    World Scientific News; 2018, 105; 157-167
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Radiologically Isolated Syndrome – a not so rare prelude to Multiple Sclerosis
    Autorzy:
    Kulczyński, Marcin
    Sapko, Klaudia
    Papuć, Ewa
    Marciniec, Michał
    Dyndor, Katarzyna
    Pankowska, Anna
    Pietura, Radosław
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1164263.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    biomarkers
    cerebro-spinal fluid
    cognitive impairment
    demyelinating diseases
    disability
    headache
    magnetic resonance imaging
    multiple sclerosis
    neurological disorders
    radiologically isolated syndrome
    Opis:
    Radiologically isolated syndrome (RIS) was defined for the first time in 2009 with an attempt to establish objective criteria of diagnosis for the patients, who underwent brain MRI scanning for a reason other than multiple sclerosis (MS), but were found to have white matter lesions in their central nervous systems (CNS) similar to those present in patients with diagnosed MS. RIS has been defined as separate entity with the presence of MRI findings strongly suggestive of MS in a patient with no neurological manifestations or other clear-cut explanation. Healthy patients may have an initial MRI procedure performed due to different reasons other than suspicion of MS, mainly because of headaches. However, a clinical examination does not reveal any signs of focal neurological deficits and there are no evidence for the focal damage in the CNS in these patients as well. Although RIS is not the first stage of multiple sclerosis in every patient, 30 up to even 45% of individuals diagnosed with this condition will present clinical symptoms in the future, within median time from 2.3 to 5.4 years depending on various researches. Most authors agree, that about 1/3 of patients with RIS will convert to clinically definite MS within 5 years of follow-up. There are some significant predictors of conversion, among others - presence of lesions in cervical and thoracic spinal cord. Moreover, patients with RIS, although asymptomatic in the meaning of classic clinical presentation of MS, are proved to experience early axonal loss, brain atrophy, increased anxiety and depression and subclinical inflammatory disease, as well as some signs of cognitive impairment. In this article we aim to make a review of the newest papers published in 2017 and 2018 concerning Radiologically Isolated Syndrome.
    Źródło:
    World Scientific News; 2018, 107; 1-11
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies